Abstract
Brain drug development is limited by the blood–brain barrier (BBB), which restricts the passage into the brain of >95% of all drug candidates intended for the CNS. The growth of future CNS drug development can be accelerated by fostering parallel growth in both CNS drug discovery and CNS drug delivery. One approach to solving the BBB problem is to target endogenous BBB transport systems, and to develop CNS drug delivery strategies that take advantage of these natural portals of entry into the brain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
